On World Asthma Day 2026, experts debunk myths around inhalers, stressing they are safe, effective, and not addictive. Early ...
For many years, the blue inhaler — medically referred to as a short-acting beta2 agonist or SABA — has been a lifeline for ...
Millions of people with asthma use the blue inhaler to help relieve the symptoms when they have an attack but a doctor is now ...
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
From asthma to COPD, inhalers are central to keeping symptoms under control—but choosing one involves more than convenience. Updated guidelines and research now factor in patient-specific health data, ...
At AstraZeneca, Andrew Menzies-Gow leads global medical strategy across two fast-moving therapy areas, focusing here on ...
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended ...
The Industrial Estate Authority of Thailand (IEAT) and AstraZeneca (Thailand) Co., Ltd. are moving forward with the Health and Well-being Enhancement Program for Workers in Industrial Estates. The ...
AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector ...
AstraZeneca’s Saphnelo approved in US for subcutaneous self-administration as a new autoinjector to treat systemic lupus erythematosus: Cambridge, UK Tuesday, April 28, 2026, 10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results